FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

07/24/14 - 20140205593 - Monovalent antibody fragments useful as therapeutics
The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment....

07/24/14 - 20140205594 - Treatment of cancer
Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101....

07/24/14 - 20140205595 - Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the...

07/24/14 - 20140205596 - Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer....

07/24/14 - 20140205597 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA...

07/24/14 - 20140205598 - Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to...

07/17/14 - - Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are...

07/17/14 - 20140199292 - Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence
The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-κB inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor...

07/17/14 - 20140199293 - Humanized antibody compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described....

07/17/14 - 20140199294 - Heterodimerized polypeptide
The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in...

07/17/14 - 20140199295 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA...

07/17/14 - 20140199296 - Cancer drug and uses
A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one...

07/17/14 - 20140199297 - Triterpene glycoside and triterpene compositions and methods of using same
In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving modification with polyethylene glycol and (b) a formulation approach involving non-covalent encapsulation in antibody targeted pol(DL-lactic acid) nanoparticles....

07/17/14 - 20140199298 - Combination treatment of cancer comprising egfr/her2 inhibitors
optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof....

07/17/14 - 20140199299 - Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target CD3 on T cells and neutralize one or more biological activities of interleukin-6 (IL-6), such as CD3 modulators including anti-CD3 antibodies and anti-IL-6 antagonists including anti-IL-6 antibodies, anti-IL-6R antagonists including anti-IL-6R antibodies, and/or...

07/17/14 - 20140199300 - Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd1 maytansinoid immunoconjugate and rituzimab
A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma....

07/10/14 - 20140193397 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods....

07/10/14 - 20140193398 - Polymalic acid-based nanobiopolymer compositions
Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for...

07/10/14 - 20140193399 - Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy...

07/10/14 - 20140193400 - Stable and soluble antibodies inhibiting tnf alpha
The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis...

07/10/14 - 20140193401 - Pertussis antibodies and uses thereof
Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided....

07/10/14 - 20140193402 - Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for...

07/10/14 - 20140193403 - Epitopes of il-17a and il-17f and antibodies specific thereto
The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them....

07/10/14 - 20140193404 - Glycosylated antibodies
The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1%...

07/10/14 - 20140193405 - Humanized anti-cd40 antibodies
Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen....

07/10/14 - 20140193406 - Methods used in identifying glioblastoma
The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy....

07/03/14 - 20140186336 - Methods of treating pterygium
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an...

07/03/14 - 20140186337 - Antitumors combinations containing antibodies recognizing specifically cd38 and bortezomib
Pharmaceutical composition comprising an antibody specifically recognizing CD38 and bortezomib....

07/03/14 - 20140186338 - Genetic products differentially expressed in tumors and the use thereof
The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with...

07/03/14 - 20140186339 - Compositions and methods for treating ocular diseases and conditions
The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions, particularly glaucoma and ocular hypertension. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing...

07/03/14 - 20140186340 - Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
Disclosed herein are methods and compositions for increasing perfusion, reducing hypoxia, reducing permeability and increasing the integrity of vasculature; e.g., in a tumor. The compositions include inhibitors of the LOXL2 enzyme. In certain of the methods, a LOXL2 inhibitor is used in combination with, and facilitates the therapeutic activity of,...

07/03/14 - 20140186341 - Methods for improving drug efficacy
The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to...

07/03/14 - 20140186342 - Compositions and methods for diagnosing and treating cancer
An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in...

07/03/14 - 20140186343 - Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed....

07/03/14 - 20140186344 - Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis
The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-1/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear....

07/03/14 - 20140186345 - Method of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin...

07/03/14 - 20140186346 - Methods of treating pain using an il-31ra or osmr-b antagonist
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated....

07/03/14 - 20140186347 - Extending time to disease progression or survival in cancer patients
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab....

07/03/14 - 20140186348 - Humanized and chimeric anti-properdin antibodies
An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3CDRS in SEQ ID NO: 9....

07/03/14 - 20140186349 - Human cdr-grafted antibody and antibody fragment thereof
A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4...

06/26/14 - 20140178363 - Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an...

06/26/14 - 20140178364 - Compositions and methods for targeting type 1 interferon producing cells
The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds....

06/26/14 - 20140178365 - Glycan-interacting compounds
The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them....

06/26/14 - 20140178366 - Preselection of subjects for therapeutic treatment based on hypoxic status
The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on...

06/26/14 - 20140178367 - Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2)
Methods of treating inflammatory diseases, e.g., diseases associated with inflammatory CD14+/CD16− monocytes, e.g., amyotrophic lateral sclerosis (ALS), stroke, and glaucoma, using compounds such as small molecules and antibodies that target CCR2 or CCL2....

06/26/14 - 20140178368 - Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
Methods for treating cancer in a patient in need thereof, with a therapeutically effective amount of an anti-4-1BB antibody in combination with a therapeutically effective amount of an ADCC-inducing antibody, are disclosed....

06/26/14 - 20140178369 - Treatment with anti-vegf antibodies
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents....

06/26/14 - 20140178370 - Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and...

06/26/14 - 20140178371 - Anti-angiogenesis therapy for the treatment of ovarian cancer
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian...

06/26/14 - 20140178372 - Methods of treating hematologic cancers
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits....

06/26/14 - 20140178373 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides...

06/26/14 - 20140178374 - Bax agonist, compositions, and methods related thereto
The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject...